BRPI0607639A2 - anticorpos para o tgfbeta - Google Patents

anticorpos para o tgfbeta

Info

Publication number
BRPI0607639A2
BRPI0607639A2 BRPI0607639-4A BRPI0607639A BRPI0607639A2 BR PI0607639 A2 BRPI0607639 A2 BR PI0607639A2 BR PI0607639 A BRPI0607639 A BR PI0607639A BR PI0607639 A2 BRPI0607639 A2 BR PI0607639A2
Authority
BR
Brazil
Prior art keywords
antibody
tgf
antibody molecules
molecules
tgfbeta
Prior art date
Application number
BRPI0607639-4A
Other languages
English (en)
Inventor
Steven R Ledbetter
Celia P Hart
Robert G Holgate
Lutz U Jermutus
Catriona L Buchanan
Alexander R Duncan
Donna K Finch
Original Assignee
Genzyme Corp
Celia P Hart
Robert G Holgate
Lutz U Jermutus
Catriona L Buchanan
Alexander R Duncan
Donna K Finch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp, Celia P Hart, Robert G Holgate, Lutz U Jermutus, Catriona L Buchanan, Alexander R Duncan, Donna K Finch filed Critical Genzyme Corp
Publication of BRPI0607639A2 publication Critical patent/BRPI0607639A2/pt
Publication of BRPI0607639B1 publication Critical patent/BRPI0607639B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

ANTICORPOS PARA O TGFBETA. A presente invenção refere-se a moléculas de anticorpo, particularmente a moléculas de anticorpo que se ligam ao Fator Transformador de Crescimento beta (TGF<225>) e aos seus usos. Mais particularmente, a invenção se refere a moléculas de anticorpo que se ligam e preferivelmente neutralizam TGF<225>1, TGF<225>2 e TGF<225>3, chamadas moléculas de anticorpo "panespecíficas", e aos usos de tais moléculas de anticorpo. Modalidades preferidas na presente invenção são moléculas de anticorpo, seja anticorpo inteiro (por exemplo, lgG, tal como lgGl ou lgG4) ou fragmentos de anticorpo (por exemplo, scFv, Fab, dAb).
BRPI0607639-4A 2005-02-08 2006-02-08 Moléculas de anticorpo humano ou fragmento de ligação a antígeno das mesmas que se ligam e neutralizam tgf-beta1, 2 e 3, uso das mesmas e composição farmacêutica BRPI0607639B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65134305P 2005-02-08 2005-02-08
US60/651,343 2005-02-08
PCT/US2006/004424 WO2006086469A2 (en) 2005-02-08 2006-02-08 Antibodies to tgfbeta

Publications (2)

Publication Number Publication Date
BRPI0607639A2 true BRPI0607639A2 (pt) 2009-09-22
BRPI0607639B1 BRPI0607639B1 (pt) 2022-04-05

Family

ID=36793677

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607639-4A BRPI0607639B1 (pt) 2005-02-08 2006-02-08 Moléculas de anticorpo humano ou fragmento de ligação a antígeno das mesmas que se ligam e neutralizam tgf-beta1, 2 e 3, uso das mesmas e composição farmacêutica

Country Status (19)

Country Link
US (11) US7723486B2 (pt)
EP (2) EP3520815B1 (pt)
JP (5) JP5174466B2 (pt)
CN (3) CN101163502A (pt)
AU (1) AU2006213875B2 (pt)
BR (1) BRPI0607639B1 (pt)
CA (2) CA2597098C (pt)
CY (1) CY1121424T1 (pt)
DK (1) DK1850873T3 (pt)
ES (2) ES2711213T3 (pt)
HU (1) HUE042689T2 (pt)
IL (3) IL184995A (pt)
LT (1) LT1850873T (pt)
MX (1) MX2007009545A (pt)
PL (2) PL3520815T3 (pt)
PT (2) PT1850873T (pt)
SI (1) SI1850873T1 (pt)
TR (1) TR201901929T4 (pt)
WO (1) WO2006086469A2 (pt)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2607422Y2 (ja) 1990-03-16 2001-09-04 株式会社東海理化電機製作所 ウエビング巻取装置
JP2607424Y2 (ja) 1990-03-16 2001-09-04 株式会社東海理化電機製作所 ウエビング巻取装置
JP2607425Y2 (ja) 1990-03-16 2001-09-04 株式会社東海理化電機製作所 ウエビング巻取装置
JP2607423Y2 (ja) 1990-03-16 2001-09-04 株式会社東海理化電機製作所 ウエビング巻取装置
US7563874B2 (en) * 1998-08-31 2009-07-21 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
CA2561686C (en) * 2004-03-31 2014-12-02 Genentech, Inc. Humanized anti-tgf-beta antibodies
CN101163502A (zh) 2005-02-08 2008-04-16 根茨美公司 针对TGFβ的抗体
EP2918288B1 (en) 2006-10-03 2017-08-16 Genzyme Corporation Use of TGF beta antagonists to treat infants at risk of developing bronchopulmonary dysplasia
DK2426144T3 (en) * 2007-02-23 2019-01-07 Merck Sharp & Dohme Manipulated Anti-IL-23P19 Antibodies
SG178804A1 (en) * 2007-02-23 2012-03-29 Schering Corp Engineered anti-il-23p19 antibodies
WO2009008916A2 (en) * 2007-03-22 2009-01-15 The Regents Of The University Of Californina Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
CA2732003A1 (en) 2008-07-31 2010-02-04 James D. Marks Antibodies that neutralize botulinum neurotoxins
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
EP3683317A3 (en) 2009-05-13 2020-09-30 Genzyme Corporation Anti-human cd52 immunoglobulins
RS59830B1 (sr) 2010-03-01 2020-02-28 Bayer Healthcare Llc Optimizovana monoklonska antitela protiv inhibitora puta faktora tkiva (tfpi)
TR201816180T4 (tr) 2010-03-12 2018-11-21 Genzyme Corp Meme kanserini tedavi etmek için kombinasyonlu tedavi.
US9243057B2 (en) 2010-08-31 2016-01-26 The Regents Of The University Of California Antibodies for botulinum neurotoxins
MX354535B (es) * 2010-09-01 2018-03-09 Genzyme Corp Star TRATAMIENTO DE INFARTO DE MIOCARDIO USANDO ANTAGONISTAS DE TGF-ß.
WO2012068531A2 (en) 2010-11-18 2012-05-24 The General Hospital Corporation Novel compositions and uses of anti-hypertension agents for cancer therapy
AR084141A1 (es) 2010-11-19 2013-04-24 Imai Toshio Anticuerpos neutralizadores anti-ccl20
PH12013502489B1 (en) 2011-06-03 2019-04-24 Xoma Technology Ltd Antibodies specific for tgf-beta
US20140308275A1 (en) 2011-07-27 2014-10-16 Inserm (Institut National De La Sante Et De La Recherche Medicale Methods for diagnosing and treating myhre syndrome
BR112014009789A2 (pt) 2011-10-26 2017-04-25 Seattle Children's Res Inst cisteamina no tratamento da doença fibrótica
US9782452B2 (en) 2011-11-22 2017-10-10 Cornell University Methods for stimulating hematopoietic recovery by inhibiting TGFβ signaling
US9518112B2 (en) 2012-03-08 2016-12-13 Ludwig Institute For Cancer Research Ltd TGF-β1 specific antibodies and methods and uses thereof
WO2013134665A1 (en) 2012-03-08 2013-09-12 Selig Sealing Products, Inc. Container sealing member with protected security component and removal tab
PL2971048T4 (pl) * 2013-03-11 2019-05-31 Genzyme Corp Zmodyfikowane przeciwciała anty-TGF-beta i fragmenty wiążące antygen
DK2970890T3 (da) 2013-03-14 2020-05-04 Brigham & Womens Hospital Inc Sammensætninger og fremgangsmåder til opformering og dyrkning af epitelstamceller
SI3312195T1 (sl) 2013-03-20 2020-02-28 Genzyme Corporation Postopki zdravljenja osteogeneze imperfecta
HUE052232T2 (hu) 2013-05-06 2021-04-28 Scholar Rock Inc Készítmények és eljárások növekedési faktor modulálására
AU2014308751B2 (en) 2013-08-22 2020-03-05 Acceleron Pharma, Inc. TGF-beta receptor type II variants and uses thereof
KR102360315B1 (ko) * 2014-05-16 2022-02-08 웰헤드 바이오로지컬 테크놀로지 코포레이션. 신장 섬유증을 억제하기 위한 진세노사이드 m1의 용도
WO2016037016A1 (en) 2014-09-03 2016-03-10 The Brigham And Women's Hospital, Inc. Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
WO2016061142A1 (en) 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
US11384350B2 (en) 2014-12-15 2022-07-12 The Regents Of The University Of California Cytotoxic molecules responsive to intracellular ligands for selective T cell mediated killing
CA3008162A1 (en) 2014-12-15 2016-06-23 The Regents Of The University Of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
CA2973978A1 (en) 2015-01-14 2016-07-21 The Brigham And Women's Hospital, Inc. Treatment of cancer with anti-lap monoclonal antibodies
CN116327915A (zh) 2015-04-03 2023-06-27 佐马技术有限公司 使用TGF-β抑制剂和PD-1抑制剂治疗癌症
EP3307772B1 (en) 2015-06-12 2020-09-09 Ludwig Institute For Cancer Research Limited Tgf-beta 3 specific antibodies and methods and uses thereof
TW201718010A (zh) * 2015-06-19 2017-06-01 健臻公司 治療原發性局部節段性腎小球硬化症之方法
ES2878188T3 (es) 2015-07-29 2021-11-18 Novartis Ag Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
EP4378957A3 (en) 2015-07-29 2024-08-07 Novartis AG Combination therapies comprising antibody molecules to pd-1
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
CN116327952A (zh) 2015-08-04 2023-06-27 阿塞勒隆制药公司 用于治疗骨髓增生性病症的方法
DK3368571T5 (da) * 2015-10-30 2024-09-30 Univ California Transformerende, vækstfaktor-beta-responsive polypeptider og fremgangsmåder til anvendelse deraf
EP3389712B1 (en) 2015-12-17 2024-04-10 Novartis AG Antibody molecules to pd-1 and uses thereof
WO2017106630A1 (en) 2015-12-18 2017-06-22 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
JP2019506153A (ja) 2016-01-08 2019-03-07 マサチューセッツ インスティテュート オブ テクノロジー 分化した腸内分泌細胞およびインスリン産生細胞の作製
CN108884127A (zh) * 2016-01-21 2018-11-23 斯克利普斯研究院 合成的阿片类疫苗
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
PL3365368T3 (pl) 2016-03-11 2023-08-21 Scholar Rock, Inc. Immunoglobuliny wiążące tgfbeta1 i ich zastosowanie
AU2017268234A1 (en) 2016-05-17 2018-12-13 Genentech, Inc. Stromal gene signatures for diagnosis and use in immunotherapy
GB201610044D0 (en) * 2016-06-08 2016-07-20 Ucb Biopharma Sprl Antibodies
WO2018027329A1 (en) * 2016-08-11 2018-02-15 Precithera, Inc. TGF-β ANTAGONIST CONJUGATES
JP2019530440A (ja) 2016-09-02 2019-10-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア インターロイキン６受容体α結合単鎖可変断片を含む方法および組成物
TW201811827A (zh) * 2016-09-05 2018-04-01 日商中外製藥股份有限公司 抗ＴＧＦ－β１抗體及使用方法
EP3551034A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
MX390321B (es) 2016-12-30 2025-03-20 Frequency Therapeutics Inc Compuestos de 1h-pirrol-2,5-diona y metodos de uso de los mismos para inducir la auto-renovacion de celulas madre/progenitoras de soporte.
WO2018129329A1 (en) 2017-01-06 2018-07-12 Scholar Rock, Inc. ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFβ1 INHIBITORS AND USE THEREOF
TWI788321B (zh) 2017-01-20 2023-01-01 美商健臻公司 骨靶向抗體
TWI787230B (zh) 2017-01-20 2022-12-21 法商賽諾菲公司 抗ＴＧＦ-β抗體及其用途
EA201991729A1 (ru) 2017-01-20 2019-12-30 Санофи Антитела к tgf-бета и их применение
BR112019023071A2 (pt) 2017-05-04 2020-06-09 Acceleron Pharma Inc proteínas de fusão do receptor tgf-beta do tipo ii e uso das mesmas
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
US11312783B2 (en) 2017-06-22 2022-04-26 Novartis Ag Antibody molecules to CD73 and uses thereof
EP3694552A1 (en) 2017-10-10 2020-08-19 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof
CN111213059B (zh) 2017-11-06 2024-01-09 豪夫迈·罗氏有限公司 用于癌症的诊断和治疗方法
CN111655288A (zh) 2017-11-16 2020-09-11 诺华股份有限公司 组合疗法
WO2019108900A1 (en) 2017-11-30 2019-06-06 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof
TWI823906B (zh) 2018-03-09 2023-12-01 美商艾吉納斯公司 抗-cd73 抗體及其使用方法
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
AU2019277029C1 (en) 2018-06-01 2024-01-04 Novartis Ag Binding molecules against BCMA and uses thereof
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
CA3105333A1 (en) * 2018-07-10 2020-01-16 Sanofi Combination therapies against cancer targeting cd38 and tgf-beta
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
US20210340238A1 (en) 2018-07-11 2021-11-04 Scholar Rock, Inc. TGFß1 INHIBITORS AND USE THEREOF
HRP20212034T1 (hr) 2018-07-11 2022-04-01 Scholar Rock, Inc. Izoformno selektivni inhibitori tgfbeta1 i njihove uporabe
US12252531B2 (en) 2018-07-11 2025-03-18 Scholar Rock, Inc. Methods of screening for high-affinity, isoform-selective TGFβ1 inhibitors
JP2021531306A (ja) 2018-07-25 2021-11-18 アドバンスド アクセラレーター アプリケーションズ エスエー 神経内分泌腫瘍の処置の方法
WO2020037326A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
JP2021533788A (ja) 2018-08-17 2021-12-09 フリークエンシー セラピューティクス インコーポレイテッド Ｊａｇ−１を上方制御することにより有毛細胞を生成するための組成物及び方法
JP7397874B2 (ja) 2018-08-30 2023-12-13 エイチシーダブリュー バイオロジックス インコーポレイテッド 多鎖キメラポリペプチドおよびその使用
CN120535649A (zh) 2018-08-30 2025-08-26 免疫生物公司 单链嵌合多肽和其用途
US11130802B2 (en) 2018-10-10 2021-09-28 Tilos Therapeutics, Inc. Anti-lap antibody variants
AU2019374496B2 (en) 2018-11-05 2026-02-05 Centre Hospitalier Universitaire Vaudois Humanized and variant TGF-β3 specific antibodies and methods and uses thereof
CA3118186A1 (en) 2018-11-05 2020-05-14 Ludwig Institute For Cancer Research Ltd Humanized and variant tgf-.beta.1 specific antibodies and methods and uses thereof
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2020128972A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
PH12021551860A1 (en) 2019-01-30 2022-05-16 Scholar Rock Inc Ltbp complex-specific inhibitors of tgf㟠and uses thereof
ES3032659T3 (en) 2019-02-15 2025-07-23 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
BR112021015672A2 (pt) 2019-02-15 2021-10-05 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona substituída e usos dos mesmos
US20220177978A1 (en) 2019-04-02 2022-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
WO2020257639A1 (en) 2019-06-21 2020-12-24 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
WO2021021991A1 (en) 2019-08-01 2021-02-04 Vaccinex,Inc. Combined inhibition of semaphorin-4d and tgfb and compositions therefor
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
MX2022004873A (es) 2019-10-23 2022-05-13 Cue Biopharma Inc Polipeptidos de tgf-?.
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
KR20220116257A (ko) 2019-12-20 2022-08-22 노파르티스 아게 골수섬유증 및 골수이형성 증후군을 치료하기 위한, 데시타빈 또는 항 pd-1 항체 스파르탈리주맙을 포함하거나 또는 포함하지 않는, 항 tim-3 항체 mbg453 및 항 tgf-베타 항체 nis793의 조합물
CA3167427A1 (en) 2020-01-11 2021-07-15 Scholar Rock, Inc. Tgfb inhibitors and use thereof
CA3169231A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of treating age-related and inflammatory diseases
US12187763B2 (en) 2020-02-11 2025-01-07 Immunitybio, Inc. Chromatography resin and uses thereof
AU2021220196A1 (en) 2020-02-11 2022-08-04 HCW Biologics, Inc. Methods of activating regulatory T cells
CR20220524A (es) 2020-03-19 2022-12-02 Genentech Inc Anticuerpos anti-tgf-beta con selectividad de isoforma y métodos de uso
CN115836087A (zh) 2020-04-29 2023-03-21 Hcw生物科技公司 抗cd26蛋白及其用途
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
CN115916199A (zh) 2020-06-23 2023-04-04 诺华股份有限公司 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
EP4204020A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
WO2022043557A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
EP4240491A1 (en) 2020-11-06 2023-09-13 Novartis AG Cd19 binding molecules and uses thereof
AU2021377176A1 (en) * 2020-11-11 2023-06-22 Hq Han Bifunctional antagonists of activin/tgf-beta and rankl and uses thereof
AU2021388155A1 (en) 2020-11-25 2023-06-15 Catamaran Bio, Inc. Cellular therapeutics engineered with signal modulators and methods of use thereof
EP4284510A1 (en) 2021-01-29 2023-12-06 Novartis AG Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
JP2024506200A (ja) 2021-02-15 2024-02-09 武田薬品工業株式会社 細胞治療用組成物及びｔｇｆ－ｂシグナル伝達を調節する方法
AU2022224584A1 (en) 2021-02-19 2023-09-21 Theripion, Inc. Paraoxonase fusion polypeptides and related compositions and methods
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
CN112940119B (zh) * 2021-04-26 2022-05-20 北京芳渟阳生生物科技有限公司 一种单克隆抗体及其与间充质干细胞外泌体的联合应用
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
WO2022256723A2 (en) 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
CA3227318A1 (en) 2021-08-11 2023-02-16 HCW Biologics, Inc. Multi-chain chimeric polypeptides and use thereof in the treatment of liver diseases
WO2023080900A1 (en) 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
CN119384289A (zh) 2022-04-13 2025-01-28 免疫生物公司 用于治疗神经炎症性障碍的多链嵌合多肽
AU2023254108B2 (en) 2022-04-13 2026-01-29 Immunitybio, Inc. Multi-chain chimeric polypeptide for use in the treatment of circardian clock gene disorder
TWI866210B (zh) 2022-05-17 2024-12-11 大陸商蘇州創勝醫藥集團有限公司 雙功能蛋白質及其製劑和用途
WO2024077095A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating bladder cancer
WO2024077166A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating lung cancer
EP4650366A1 (en) * 2023-01-09 2025-11-19 Beijing Tuo Jie Biopharmaceutical Co. Ltd. Tgfbeta1 binding molecule, garp-tgfbeta1 binding molecule and medical use thereof
EP4509522A1 (en) 2023-08-16 2025-02-19 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft A tgfbeta switch receptor, a nucleic acid encoding it, cells and pharmaceutical compositions comprising the same
WO2025058919A1 (en) * 2023-09-12 2025-03-20 Lyell Immunopharma, Inc. Bispecific chimeric antigen receptors and use thereof
WO2025140212A1 (en) * 2023-12-26 2025-07-03 Laekna Therapeutics Shanghai Co., Ltd. Multispecific binding agents comprising anti-fibroblast activation protein (fap) antibodies and one or more monovalent ligand traps and uses thereof
US12605349B2 (en) 2024-09-05 2026-04-21 Orbus Therapeutics, Inc. Methods of treating grade 3 astrocytoma

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2056642B (en) 1979-08-08 1983-05-11 Dawson Int Radio frequency drying of textile material
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5571714A (en) * 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
US20040028682A1 (en) * 1989-09-29 2004-02-12 Border Wayne A. Inhibiting transforming growth factor beta to prevent accumulation of extracellular matrix
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992010423A1 (en) 1990-12-10 1992-06-25 Panama Engineering Pty Limited Fork-lift attachment
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
US5269388A (en) 1991-11-12 1993-12-14 Stress-Tek, Inc. Weighing bed
US5543143A (en) * 1992-03-06 1996-08-06 Corixa Corporation Method for activating macrophages/monocytes
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
US5824655A (en) 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
HU230048B1 (hu) 1996-02-09 2015-06-29 Abbvie Biotechnology Ltd Humán TNFalfa-kötő antitestek alkalmazása
WO1997032600A1 (fr) 1996-03-10 1997-09-12 Meiji Milk Products Co., Ltd. Agent immunotherapeutique a base peptidique pour le traitement des allergies
EP1137941B2 (en) 1998-12-10 2013-09-11 Bristol-Myers Squibb Company Protein scaffolds for antibody mimics and other binding proteins
EP2168984B1 (en) * 1999-03-25 2012-08-29 Abbott GmbH & Co. KG Human antibodies that bind human IL-12 and methods for producing
US6492497B1 (en) * 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
EP1259615B1 (en) 2000-03-03 2008-11-12 Cambridge Antibody Technology Limited Antibodies against eotaxin and their use
US20030224501A1 (en) * 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
HRP20030426A2 (en) * 2000-12-06 2005-04-30 Applied Research Systems Ars Holding N.V. Use of sarp-1 for the treatment and/or preventionof scleroderma
CN1688549A (zh) * 2002-08-23 2005-10-26 麒麟麦酒株式会社 具有TGFβ抑制活性的化合物和含所述化合物的药用组合物
US20060286105A1 (en) * 2003-04-30 2006-12-21 Steven Ledbetter Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency
WO2005010049A2 (en) 2003-07-09 2005-02-03 Eli Lilly And Company Tgf-beta1 ligands
GB0407315D0 (en) * 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
JP2005112812A (ja) * 2003-10-09 2005-04-28 Zeria Pharmaceut Co Ltd リン酸化部位特異的抗体及びそれを用いたスクリーニング方法
DK1702059T3 (da) 2003-12-09 2013-03-04 Novozymes Inc Fremgangsmåder til eliminering og reduktion af ekspression af gener i filamentøse svampestammer
CA2561686C (en) 2004-03-31 2014-12-02 Genentech, Inc. Humanized anti-tgf-beta antibodies
KR100749566B1 (ko) * 2004-04-21 2007-08-16 이화여자대학교 산학협력단 Ａｌｋ5 및/또는 ａｌｋ4 억제제로 유효한 2-피리딜이치환된 이미다졸 유도체
CN101163502A (zh) 2005-02-08 2008-04-16 根茨美公司 针对TGFβ的抗体
ITMI20110376A1 (it) 2011-03-10 2012-09-11 Wilic Sarl Aerogeneratore raffreddato a fluido
DE102011078333A1 (de) 2011-06-29 2013-01-03 Siemens Aktiengesellschaft Überspannungsableiter

Also Published As

Publication number Publication date
CN101163502A (zh) 2008-04-16
HK1201859A1 (en) 2015-09-11
US20140127230A1 (en) 2014-05-08
IL184995A (en) 2013-04-30
ES2905923T3 (es) 2022-04-12
JP2017217003A (ja) 2017-12-14
JP6341945B2 (ja) 2018-06-13
US7723486B2 (en) 2010-05-25
LT1850873T (lt) 2019-04-10
MX2007009545A (es) 2008-03-11
US20210061897A1 (en) 2021-03-04
US20130243788A1 (en) 2013-09-19
CY1121424T1 (el) 2020-05-29
US8383780B2 (en) 2013-02-26
SI1850873T1 (sl) 2019-05-31
US20070264255A1 (en) 2007-11-15
TR201901929T4 (tr) 2019-03-21
US20230078449A1 (en) 2023-03-16
US8591901B2 (en) 2013-11-26
AU2006213875B2 (en) 2010-08-19
JP2008529503A (ja) 2008-08-07
JP2016128512A (ja) 2016-07-14
US12612453B2 (en) 2026-04-28
US10174108B2 (en) 2019-01-08
CA2597098A1 (en) 2006-08-17
CN104177497A (zh) 2014-12-03
JP2013031444A (ja) 2013-02-14
JP2015003917A (ja) 2015-01-08
PT3520815T (pt) 2022-02-02
US20070134246A1 (en) 2007-06-14
US9481726B2 (en) 2016-11-01
HK1201860A1 (en) 2015-09-11
CN104177497B (zh) 2018-01-16
BRPI0607639B1 (pt) 2022-04-05
EP1850873A4 (en) 2012-06-13
PT1850873T (pt) 2019-02-19
WO2006086469A2 (en) 2006-08-17
EP1850873B1 (en) 2018-11-28
IL184995A0 (en) 2007-12-03
PL3520815T3 (pl) 2022-04-11
AU2006213875A1 (en) 2006-08-17
JP6463807B2 (ja) 2019-02-06
US20110008364A1 (en) 2011-01-13
EP1850873A2 (en) 2007-11-07
ES2711213T3 (es) 2019-04-30
JP5174466B2 (ja) 2013-04-03
IL225752A (en) 2017-10-31
CA2597098C (en) 2016-08-02
IL255078B (en) 2021-01-31
DK1850873T3 (en) 2019-03-18
US20150284456A1 (en) 2015-10-08
US9090685B2 (en) 2015-07-28
US20190177406A1 (en) 2019-06-13
WO2006086469A3 (en) 2007-04-19
US20170066821A1 (en) 2017-03-09
US10781252B2 (en) 2020-09-22
CN104151427A (zh) 2014-11-19
HUE042689T2 (hu) 2019-07-29
IL255078A0 (en) 2017-12-31
IL225752A0 (en) 2013-06-27
JP5726140B2 (ja) 2015-05-27
PL1850873T3 (pl) 2019-06-28
EP3520815A1 (en) 2019-08-07
US20060251658A1 (en) 2006-11-09
CA2930677A1 (en) 2006-08-17
CN104151427B (zh) 2017-09-08
JP6005703B2 (ja) 2016-10-12
EP3520815B1 (en) 2021-11-17

Similar Documents

Publication Publication Date Title
TR201901929T4 (tr) TGFBeta&#39;ya antikorlar.
BRPI0611414B8 (pt) anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga ao tweak humano, composição farmacêutica e seus usos
BRPI0607486A2 (pt) anticorpo l243 humanizado, anticorpo biespecìfico ou fragmentos de ligação a antìgeno dos mesmos, composição farmacêutica, kit e uso dos referidos anticorpos
MX2024004322A (es) Anticuerpos que comprenden regiones constantes pesadas modificadas.
WO2010102276A3 (en) Humanized anti-cd19 antibody formulations
NZ597023A (en) Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same
BR112017010094A2 (pt) anticorpos compreendendo regiões constantes de cadeias pesadas modificadas
PE20091342A1 (es) Inmunoglobulinas
GEP20104922B (en) Antibodies to m-csf
UA92504C2 (en) Anti-myostatin monoclonal antibody
EA201100527A1 (ru) Биологические продукты
CR20120587A (es) Moléculas de unión al antígeno que fijan egfr, vectores que las codifican y uso de las mismas
BRPI0821658B8 (pt) anticorpo monoclonal humano ou um fragmento de ligação ao antígeno do mesmo que se liga a hnkg2d e seus usos
PE20090768A1 (es) Metodos y composiciones para el tratamiento de enfermedades alergicas
WO2007062245A3 (en) Human monoclonal antibody human cd134 (ox40) and methods of making and using same
AR065921A1 (es) Anticuerpos anti-ige
BR112012006492A2 (pt) proteína de fusão de anticorpo multivalente, e, ligação de albumina
MA33402B1 (fr) Compositions et procédés de ciblage de la proteine c3b de complément par des anticorps
NO20081124L (no) Anti-CD 3 antistoff-formuleringer
EP2511301A3 (en) Human antibodies to ERBB2
EP2684889A3 (en) Multivariable antigens complexed with targeting humanized monoclonal antibody
WO2006099698A3 (en) Novel anti-plgf antibody
BRPI0416141B8 (pt) anticorpo anti-cd52 modificado, composição farmacêutica, vetores de expressão, e método para preparar uma imunoglobulina
CO6260104A2 (es) Anticuerpos contra la il-25
SI2542257T1 (en) Optimized monoclonal antibodies against Tissue Factor Pathway Inhibitor (TFPI)

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: REF. A RPI NO 2150 DE 20/03/2012. ANULACAO DA EXIGENCIA 6.6 POR TER SIDO INDEVIDA. REQUERENTE NAO APRESENTOU RESPOSTA A EXIGENCIA CONFORME DISPOE A RESOLUCAO 207 DE 24/04/2009, ENTRETANTO, A RESPOSTA CONSTA NO FORMULARIO DE DEPOSITO.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/02/2006, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.